US biotechs Gilead Sciences (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) on Saturday announced longer-term efficacy and safety results from Arm A1 of the Phase II EDGE-Gastric study.
These updated data show consistent objective response rate (ORR) and provide mature progression-free survival (PFS) in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma (upper GI cancers). The ongoing, multi-arm, global Phase II EDGE-Gastric study is evaluating the safety and efficacy of various combinations of the Fc-silent anti-TIGIT antibody domvanalimab plus the anti-PD-1 monoclonal antibody zimberelimab and chemotherapy in this patient population.
The results wer presented during the American Society of Clinical Oncology (ASCO) Plenary Series: Rapid Abstract Updates session by Dr Yelena Janjigian, chief, gastrointestinal oncology, Memorial Sloan Kettering Cancer Center, and a principal investigator for the EDGE-Gastric study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze